Loading…
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $761M | $47M | $100M | $142M | 15.4% | 12.8% | -29.4% |
| 2024 | $675M | $138M | $141M | $196M | 20.8% | 39.9% | 33.0% |
| 2023 | $482M | $110M | $106M | $127M | 20.9% | 20.0% | 4.7% |
| 2022 | $402M | $116M | $101M | $120M | 20.2% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 401.86 | 482.38 | 675.04 | 761.41 |
| Cost Of Revenue | - | 5.38 | 6.48 | 10.88 | 12.98 |
| Gross Profit | - | 396.47 | 475.89 | 664.16 | 748.43 |
| Operating Expense | - | 283.84 | 368.61 | 527.21 | 703.63 |
| Operating Income | - | 112.63 | 107.28 | 136.95 | 44.80 |
| EBITDA | - | 116.08 | 109.64 | 138.29 | 46.69 |
| EBIT | - | 112.63 | 107.28 | 136.95 | 44.80 |
| Pretax Income | - | 116.19 | 124.56 | 161.49 | 66.46 |
| Tax Provision | - | 14.77 | 18.42 | 20.28 | -33.19 |
| Net Income | - | 101.42 | 106.14 | 141.21 | 99.65 |
| Net Income Common Stockholders | - | 101.29 | 105.50 | 139.73 | 98.17 |
| Total Expenses | - | 289.22 | 375.09 | 538.09 | 716.61 |
| Interest Income | - | 3.56 | 17.27 | 24.54 | 21.67 |
| Research And Development | - | 130.99 | 184.35 | 246.89 | 254.91 |
| Selling General And Administration | - | 152.85 | 184.26 | 280.32 | 448.72 |
| Normalized EBITDA | - | 116.08 | 109.64 | 138.29 | 46.69 |
| Normalized Income | - | 101.42 | 106.14 | 141.21 | 99.65 |
| Market Cap | 4,944.85 | 4,944.85 | 4,944.85 | 4,944.85 | 4,944.85 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Corcept Therapeutics Incorporatedthis co. | CORT | $4.8B | 49.62↑ premium | 7.63 | 15.4% | 103.46 |
| Alkermes plc | ALKS | $5.5B | 22.97 | 3.05 | 13.3% | 15.81 |
| PTC Therapeutics, Inc. | PTCT | $5.4B | 8.29 | -27.55 | -332.5% | 8.31 |
| TG Therapeutics, Inc. | TGTX | $5.3B | 13.08 | 9.02 | 69.0% | 44.82 |
| Apellis Pharmaceuticals, Inc. | APLS |
| 2021 |
| - |
| - |
| - |
| - |
| - |
| - |
| - |
| $5.1B |
| 233.78 |
| 14.14 |
| 6.0% |
| 74.89 |
| Waystar Holding Corp. | WAY | $4.5B | 43.50 | 1.26 | 2.9% | 16.17 |
| Indivior Pharmaceuticals, Inc. | INDV | $4.2B | 19.29 | -40.92 | -212.1% | 13.84 |
| Merit Medical Systems, Inc. | MMSI | $4.1B | 31.84 | 2.58 | 8.1% | 13.45 |
| Amneal Pharmaceuticals, Inc. | AMRX | $3.9B | 55.43 | -56.42 | -101.8% | 10.60 |
| Peer Median | - | 27.40 | 1.92 | 4.5% | 14.83 | |